For Research Use Only. Not for Clinical Use.

Fig.1 Overview of albumin binding. (Hoogenboezem, 2018)

Creative Biolabs is a trusted partner in half-life extension services. Our scientists have rich experience in this field, and we can provide multiple strategies of half-life extension to meet the unique requirements of every client. The short half-life of therapeutic molecules restricts their widespread applications. Half-life extension has been recognized as a promising strategy to broaden the uses of biotherapeutics by increasing the time between applications. Various half-life extension strategies have been utilized for generating longer therapeutics. Covalently binding therapeutic molecules to albumin is a potential method to improve their pharmacokinetic features.

Introduction of Covalent Attachment to Albumin

The covalent bond between the natural albumin and the therapeutic molecules can be formed in situ. The main method of in situ covalent attachment of albumin utilizes the 34 amino acid cysteine of albumin. Furthermore, covalently binding exogenous albumin with chemotherapeutics can obtain the same benefits as the binding of endogenous albumin.

Applications of Covalent Attachment

The covalent attachment has been used to improve the pharmacokinetic properties of a wide range of target molecules therapeutics ranging from small molecule drugs to biologics. Small molecules drugs such as methotrexate, doxorubicin, and curcumin are coupled to albumin in the development of anticancer and anti-rheumatic therapeutics. A variety of peptides including Exendin-4 and insulin have been successfully manufactured. In addition, peptides were modified to formate the conjugation via new technology.

Fig.2 General methods of covalently conjugating small molecules onto albumin. (Liu, 2016)

Covalent Attachment to Albumin

Among the half-life extension strategies, the covalent attachment of therapeutic molecules to albumin has been widely used. After years of intensive research, numerous effective therapeutic molecules formulated with albumin have been gained by the covalent conjugation of molecules to albumin in our team. Based on our professional knowledge and advanced platform, Creative Biolabs provides a variety of services, including covalently binding small molecules drugs, peptides, and other therapeutic molecules to albumin.

Features of Our Services

• Advanced platform and reliable technology
• The fully customizable design of therapeutic molecules
• Short cycle and good quality
• Reasonable price and high-quality after-sales service

For more information on our half-life extension services, please feel free to contact us.

References

1. Hoogenboezem, E. N.;Duvall, C. L.Harnessing albumin as a carrier for cancer therapies. Advanced drug delivery reviews. 2018, 130: 73-89.
2. Liu, Z.; Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chemical Society Reviews. 2016, 45(5): 1432-1456.